Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7779]

FDA approval for new imaging agent for recurrent prostate cancer

FDA approval for new imaging agent for recurrent prostate cancer

First trial in humans of “minicells”: a completely new way of delivering anti-cancer drugs

First trial in humans of “minicells”: a completely new way of delivering anti-cancer drugs

Mesothelioma drug slows disease progression in patients with an inactive NF2 gene

Mesothelioma drug slows disease progression in patients with an inactive NF2 gene

NICE recommends vemurafenib for advanced malignant melanoma and a mutated BRAF gene

NICE recommends vemurafenib for advanced malignant melanoma and a mutated BRAF gene

Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway

Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway

New targeted therapy for advanced prostate cancer shows anti-tumour activity in phase I clinical trials

New targeted therapy for advanced prostate cancer shows anti-tumour activity in phase I clinical trials

Positive NICE decision on ipilimumab, the first treatment for advanced melanoma to be licensed in the UK for over 30 years

Positive NICE decision on ipilimumab, the first treatment for advanced melanoma to be licensed in the UK for over...

New monoclonal antibody inhibits tumour growth in advanced solid tumours in a phase I clinical trial

New monoclonal antibody inhibits tumour growth in advanced solid tumours in a phase I clinical trial

Scientists test 5000 combinations of 100 existing cancer drugs to find more effective treatments

Scientists test 5000 combinations of 100 existing cancer drugs to find more effective treatments

NCRI 2012: Highlights from Monday 5 November

NCRI 2012: Highlights from Monday 5 November

More from ecancer